Child-Pough C patients with Liver cirrhosis and Proton Pump Inhibitors Use as Independent Risks of Spontaneous Bacterial Peritonitis

Session

Nursing and Medical Sciences

Description

Since in the early 1980s, proton pump inhibitors (PPIs) have been used worldwide for a more of indications. Long term administration of PPIs for different indications, we can see more their side effects, including the possibility of an increased risk of spontaneous bacterial peritonitis (SBP). Association between PPI use and SBP development in cirrhotic patients is conflicting. Our aim was to evaluate for a possible association between PPIs use and Child-Pough sore on SBP development in cirrhotic patients.

Methods: A retrospective analysis of 18 out 24 patients with SBP from 460 liver cirrhotic patients were taken PPIs. Included patients with a diagnosis of liver cirrhosis and SBP divided into two groups: the first group included all cirrhotic patients who did not use PPIs and the second group included all cirrhotic patients who were on PPIs at home. Was investigated and after affiliation for Child-Pough score in the gropus wich had received one out all PPIs.

Results: In our analysis, SBP occurred in 3.91% (18/460 patients) of the included cirrhotic patients whether they were actively taking PPIs and 6/460 patients with SBP wich not received PPI. On statistically analysis, PPI use was the strongest predictor for SBP in cirrhotic patients (odds ratio (OR) = 3; 95% confidence interval (CI): 2.62 - 4.58, P value < 0.01. In addition, patients on Child-Pough C, with severe hypoalbuminaemia and prolonged PT (prothrombine time) had more chance for development of SBP (Dmax=0.22

Conclusions: Our retrospective cohort analysis has shown that the use of PPIs in patients with liver cirrhosis and decompensated liver cirrhosis are independent predicting risk factor for SBP development. We recommend that PPI therapy should be avoided or administered with caution in patients with cirrhosis.

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-550-95-6

Location

UBT Lipjan, Kosovo

Start Date

28-10-2023 8:00 AM

End Date

29-10-2023 6:00 PM

DOI

10.33107/ubt-ic.2023.198

This document is currently not available here.

Share

COinS
 
Oct 28th, 8:00 AM Oct 29th, 6:00 PM

Child-Pough C patients with Liver cirrhosis and Proton Pump Inhibitors Use as Independent Risks of Spontaneous Bacterial Peritonitis

UBT Lipjan, Kosovo

Since in the early 1980s, proton pump inhibitors (PPIs) have been used worldwide for a more of indications. Long term administration of PPIs for different indications, we can see more their side effects, including the possibility of an increased risk of spontaneous bacterial peritonitis (SBP). Association between PPI use and SBP development in cirrhotic patients is conflicting. Our aim was to evaluate for a possible association between PPIs use and Child-Pough sore on SBP development in cirrhotic patients.

Methods: A retrospective analysis of 18 out 24 patients with SBP from 460 liver cirrhotic patients were taken PPIs. Included patients with a diagnosis of liver cirrhosis and SBP divided into two groups: the first group included all cirrhotic patients who did not use PPIs and the second group included all cirrhotic patients who were on PPIs at home. Was investigated and after affiliation for Child-Pough score in the gropus wich had received one out all PPIs.

Results: In our analysis, SBP occurred in 3.91% (18/460 patients) of the included cirrhotic patients whether they were actively taking PPIs and 6/460 patients with SBP wich not received PPI. On statistically analysis, PPI use was the strongest predictor for SBP in cirrhotic patients (odds ratio (OR) = 3; 95% confidence interval (CI): 2.62 - 4.58, P value < 0.01. In addition, patients on Child-Pough C, with severe hypoalbuminaemia and prolonged PT (prothrombine time) had more chance for development of SBP (Dmax=0.22

Conclusions: Our retrospective cohort analysis has shown that the use of PPIs in patients with liver cirrhosis and decompensated liver cirrhosis are independent predicting risk factor for SBP development. We recommend that PPI therapy should be avoided or administered with caution in patients with cirrhosis.